ライフサイエンスコーパス: limited success

1 Limited success in the clinical management and a persist

2 Limited success of previous genetics studies may be attr

3 Limited successes in P450 3A4 active-site structure stud

4 Limited successes of gene finding for major depressive d

5 or PVR is surgical intervention, which has a limited success rate that diminishes in patients with re

6 uctures using high frequencies, but achieved limited success.

7 ploitation as a clinical target has achieved limited success and novel molecular targets are required

8 ast growth factor (FGF) family, has achieved limited success in protein formulations.

9 unity-based screening programs have achieved limited success due to lack of follow-up of screened pat

10 man gene therapy of stem cells have achieved limited success partly because of low gene transfer effi

11 n using extracorporeal systems have achieved limited success.

12 Cancer vaccine therapies have only achieved limited success when focusing on effector immunity with

13 servation subsidy schemes have only achieved limited success.

14 Although limited success was achieved, these studies established

15 ut the small number of affected families and limited success in validating candidates have impeded ge

16 Until recently, there had been limited success in identifying the specific genetic vari

17 s up to about 20,000 daltons, there has been limited success in achieving good mass resolution at hig

18 ies in clinical applications, there has been limited success in extending engineered RNA devices to m

19 possible in all patients and there has been limited success in generating TIL in other cancers.

20 or depressive disorder (MDD), there has been limited success in identifying replicable genetic risk l

21 a model polygenic trait, but there has been limited success in identifying the genes underlying its

22 While there has been limited success in inhibiting the protein directly, phas

23 and speed of identification, there has been limited success in the efforts that have been made to mo

24 ve in the treatment of GISTs, there has been limited success in the treatment of mastocytosis.

25 rs work to understand cancer, there has been limited success to effectively combine forces and collab

26 s of men in the US, however, there have been limited successes so far in its therapy.

27 sfer has generated considerable interest but limited success.

28 logical catalysts, or simplified mimics, but limited success has been achieved.

29 therapy has a long history with striking but limited success in patients with melanoma.

30 Despite limited success in each of these categories, everyone to

31 ave encountered practical challenges and had limited success.

32 through the generation of tissue culture had limited success for Setaria viridis, an emerging C4 mono

33 neurohormones on the kidney have so far had limited success.

34 Although the former had limited success, the role of rare genetic events, such a

35 h threshold for detection have generally had limited success, with high false-positive rates and subt

36 ce using specific inhibitors of P-gp has had limited success and has faced many therapeutic challenge

37 re anorectic, and dietary counseling has had limited success at increasing their nutrient intake.

38 f vaccines based on protein antigens has had limited success because of delivery issues.

39 ne transfer vehicles in this setting has had limited success because of silencing of transgene expres

40 ene therapy using proapoptotic genes has had limited success because the therapy is prone to cause si

41 mic delivery of the TNFalpha protein has had limited success clinically because of severe dose-limiti

42 ignals by sequence homology searches has had limited success due to sequence heterogeneity.

43 Oral immunotherapy has had limited success in establishing tolerance in food allerg

44 ving human brain, but this technique has had limited success in tracing pathways into gray matter.

45 irable for various applications, but has had limited success owing to thermodynamic favorability of s

46 antibodies to target tumor antigens has had limited success, partially due to the large size of IgG

47 ntion with prophylactic drug therapy has had limited success, therefore alternative approaches are re

48 ceptibility genes and their variants has had limited success.

49 ute graft-versus-host disease (GVHD) has had limited success.

50 derived modulators of bone formation has had limited success.

51 ,25-dihydroxyvitamin D(3) (1,25D(3)) has had limited success.

52 kidneys for pharmacologic treatment has had limited success.

53 sting syndrome in persons with AIDS, has had limited success.

54 ide effects and less abuse potential has had limited success.

55 T790M with irreversible inhibitors have had limited success and are associated with toxicity due to

56 lectivity in reactions of this type have had limited success and have not been related to activation

57 These interventions have had limited success and have not systematically incorporated

58 Previous investigations have had limited success and/or require unique environments that

59 trates used to inhibit AGT activity have had limited success because of dose-limiting myelotoxicity.

60 is set of reference protein spectra have had limited success because of inaccuracies arising from seq

61 ponent, genetic association studies have had limited success detecting common variants which influenc

62 cogenic proteins in astrocytes, but have had limited success due to low tumour penetrance or limited

63 enetic modification of the Ad fiber have had limited success due to structural conflicts between the

64 expression divergence in orthologs have had limited success for two primary reasons.

65 effects of cocaine; however, SSRIs have had limited success in clinical trials for cocaine abuse, po

66 ogeneity, candidate gene approaches have had limited success in finding high-risk alleles in most cas

67 Although case-control SNP-GWAS have had limited success in identifying common genetic variants f

68 molecular genetic analyses to date have had limited success in identifying specific loci responsible

69 Although candidate gene studies have had limited success in identifying susceptibility loci, geno

70 ical and anatomical prognosticators have had limited success in predicting clinical trajectories.

71 Prognostic risk models have had limited success in predicting coronary events in subject

72 orescent protein (GFP)-based probes have had limited success in recording electrical activity of neur

73 revious genetic association studies have had limited success in robustly identifying risk loci.

74 rs; however, leukotriene inhibitors have had limited success in the clinic.

75 ilar efforts for nonmelanoma tumors have had limited success with few antigens identified.

76 somes in mouse embryonic stem cells have had limited success with many other cell types, especially n

77 inically useful prognostic subtypes have had limited success, a recent report showed that machine-lea

78 cal interventions to prevent stroke have had limited success, but technological developments offer im

79 infections among household members have had limited success, likely due to the multiplicity of poten

80 Unlike previous methods which have had limited success, this method allows for correlations ind

81 uman health losses, control efforts have had limited success.

82 restore acidified streams and biota have had limited success.

83 rmount ABC-transporter-mediated MDR have had limited success.

84 primarily on emergency departments have had limited success.

85 ing specific inflammatory mediators have had limited success.

86 hat persist without causing disease have had limited success.

87 ify genetic susceptibility variants have had limited success.

88 with traditional narrowband stimuli have had limited success.

89 l treatments, although widely used, have had limited success.

90 operties of mammalian KSR, however, have had limited success.

91 s currently available, such methods have had limited success.

92 orts to reverse this gene silencing have had limited success.

93 improvements in populations' health have had limited success.

94 lar space using electron microscopy have had limited success; however, a biophysical approach based o

95 cular RCTs more inclusive appear to have had limited success; thus, women and elderly persons remain

96 corporating LP ablation and pace-mapping had limited success in patients with NICM compared with ICM,

97 rected gene therapy approaches have only had limited success in Ppt1(-/-) mice.

98 Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitati

99 resectability using noninvasive imaging has limited success, with most patients having metastases at

100 Because treatment often has limited success, new approaches must be identified.

101 nfections and DENV disease pathogenesis, has limited success to date.

102 rrent methods is that shotgun proteomics has limited success at detecting many low abundance proteins

103 vative treatment and laser therapy both have limited success in sealing the leaks and are not as effe

104 Kinase inhibitors have limited success in cancer treatment because tumors circu

105 entifying intraintestinal fecal Stx may have limited success.

106 ntial because current treatment options have limited success in achieving durable endpoints, and anti

107 at molecular and cellular levels resulted in limited success of their clinical translation.

108 single blood sample, studies have indicated limited success using genetic and metabolomics informati

109 alone have shown little efficacy, indicating limited success in modulating neuroplasticity, especiall

110 engineered nanostructured materials has met limited success compared with that which has evolved in

111 n of these molecules in soluble form has met limited success, presumably due to their large size, het

112 multiple, simultaneous interactions has met limited success.

113 man sources, such as septic systems, has met limited success.

114 ngineer new recognition specificity have met limited success.

115 eceptor-based computational methods have met limited success.

116 or tumor-involved endothelial cells have met limited success.

117 imidazole were also performed but with more limited success.

118 nels to TTX remains poor, in part because of limited success in functional expression of these channe

119 cB as a counter-selection method has been of limited success due to the presence of endogenous sacBC

120 ional one-drug-one-gene approach has been of limited success in modern drug discovery.

121 s, particularly children, which have been of limited success.

122 mTOR inhibitors are, however, of limited success.

123 Available liver support systems are still of limited success at improving survival.

124 mmercially available bacterial strains offer limited success.

125 Current smoking cessation therapies offer limited success, as relapse rates remain high.

126 They achieved only limited success as they all suffered from the high false

127 ic approach, but thus far have achieved only limited success in the clinic.

128 ased immunohistochemistry have achieved only limited success.

129 However, there has been only limited success in developing cold-hardy cultivars.

130 However, there has been only limited success in isolating SC cells.

131 treatments have been tested in ASD, but only limited success has been achieved.

132 for rare and super rare genome cutting, only limited success has been achieved.

133 So far there exists only limited success of attaining both strength and toughness

134 es where chemical techniques have found only limited success is biofouling of feed channels in high-p

135 maging for diagnosis, however, have had only limited success in diagnosing patients who are independe

136 Neuroimaging studies, however, have had only limited success in elucidating the role of the hippocamp

137 ever, gene expression profiling has had only limited success in identifying therapeutic targets.

138 des with unusual stoichiometry have had only limited success in spite of several theoretical predicti

139 dia and enhanced consent forms have had only limited success.

140 vercome the problem of hypoxia have had only limited success.

141 rials used for adhesion prevention have only limited success.

142 However, only limited success has been achieved in clinical applicatio

143 Until now, only limited success has been achieved in controlling pollen

144 eutic intervention often leads to no or only limited success.

145 s targeting immunological pathways show only limited success.

146 nsic to glioma cells have translated to only limited success; effective therapeutic strategies will n

147 ystonia has been a difficult area, with only limited success from medical therapies.

148 r, but current strategies have met with only limited success in clinical and preclinical studies.

149 as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas.

150 ly developed for therapeutic uses, with only limited success to date.

151 tabolic strategies have so far met with only limited success, although recent findings, in particular

152 s with chronic heart failure (HF), with only limited success.

153 ials in hope of circumventing MDR, with only limited success.

154 s, although these systems have met with only limited success.

155 mising CO2-based processes has met with only limited success.

156 empts to imprint proteins have met with only limited success.

157 ence of protein stability have met with only limited success: agreement with experimental results has

158 the mechanisms underlying neuropathic pain, limited success in therapeutic approaches have been atta

159 Given the previously limited success in enhancing siRNA potency with chemical

160 all of the efforts so far have only produced limited success.

161 ferent modalities, they have achieved rather limited success for other parts of the body.

162 Strategies that have received limited success in the treatment of ischemic injury, whi

163 phore engineering for fluorescence recovery, limited success has been achieved for structurally uncon

164 st few years, but their application has seen limited success beyond a few tractable species and tissu

165 n delivered to the subretinal space but show limited success when delivered to the vitreous due to th

166 on studies in frontotemporal dementia showed limited success in identifying associated loci.

167 linical trials with imatinib mesylate showed limited success due to normal tissue toxicity.

168 e current immunosuppressive therapies showed limited success in maintaining long-term islet survival

169 Protein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood

170 ECG measures (eg, QT dispersion) have shown limited success and inconsistencies.

171 simplified fragmentation patterns have shown limited success for the de novo sequencing of multiply c

172 a means of enzyme replacement and have shown limited success.

173 herapeutic inhibition of PI3K has only shown limited success in clinical trials.

174 ver, biological therapies have achieved some limited success.

175 tion of breast cancer risk has met with some limited success, perhaps because effects on breast cance

176 ntagonist began several years ago, with some limited success.

177 a decade ago but has not met with more than limited success in a few isolated instances.

178 The limited success in predicting siRNA potency being report

179 The limited success in understanding the pathophysiology of

180 The limited success of cancer immunotherapy is often attribu

181 The limited success of IFN-alpha therapy for clinical treatm

182 The limited success of the sole use of monoclonal antibodies

183 The limited success of this approach may be related to the a

184 The limited success of this approach, together with the reco

185 The limited success seen in cancer immunotherapy signifies t

186 The limited success with free antisense ONs in hematologic m

187 ddictive properties of tobacco smoke and the limited success of current approaches to cessation of sm

188 tibiotic-resistant bacterial strains and the limited success of currently available pharmaceuticals u

189 We attribute the limited success of translation to various factors, chief

190 immunity, a conclusion that may explain the limited success of most subunit vaccine protocols design

191 These results may explain the limited success reported thus far from clinical trials o

192 sizes was observed, possibly explaining the limited success of bioinformatics in identifying regulat

193 One hypothesis for the limited success of cloning via SCNT (1%-5%) is that the

194 Declining responsiveness may account for the limited success of neurotransmitter replacement therapy

195 One of the principal reasons for the limited success of therapeutic vaccination is that virus

196 Given the limited success of traditional methods for producing clu

197 of knowledge is particularly notable in the limited success of vectors for the delivery of combinati

198 In view of the limited success obtained with other treatments in this m

199 in a major clinical challenge because of the limited success of existing therapies.

200 usually offered at the refractory stage, the limited success rate of glaucoma drainage implant in ter

201 In tandem, the limited success of nonreplicative adenoviral vectors in

202 term systemic corticosteroids, despite their limited success, high recurrence rate, and incidence of

203 membrane-bound peptides, there has been very limited success in achieving alignment for functional me

204 (MCI) as a prodrome for AD has also had very limited success.

205 computational algorithms typically have very limited success in genome-scale studies.

206 MHC class I-restricted T cells, has met very limited success with class II peptide-MHC complex tetram

207 ntal impact, but these efforts have met very limited success.

208 ol of protein pharmaceuticals, met with very limited success in detection and characterization of con

209 C16-targeted therapy, but have met with very limited success.

210 e or gene sets have been proposed, there was limited success in developing methods for differential i

211 l (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmona

212 stent atrial fibrillation is associated with limited success rates and often requires multiple proced

213 ansgenic approaches have been attempted with limited success.

214 productivity at each step and attempts, with limited success, to put each in the context of an entire

215 e efficacy of existing antibiotics, but with limited success.

216 nts used self-management strategies but with limited success.

217 a in an effort to achieve this goal but with limited success.

218 mprove the precision of classification, with limited success.

219 hose that have been tried in the clinic with limited success and those currently under clinical devel

220 and minor actinides (that is, Am, Cm), with limited success.

221 biodegradable polymers, and composites with limited success.

222 tion efforts focus on mosquito control, with limited success.

223 growth have been attempted for decades with limited success.

224 ug-delivery systems have been developed with limited success for tumor chemo-photothermal therapy.

225 d antibody therapy, have been developed with limited success.

226 to improve thiopurine therapy, however with limited success.

227 omotes and enhances anti-tumor immunity with limited success on large tumors in mice.

228 erential susceptibility have been made, with limited success.

229 , effectiveness in cell culture has met with limited success and seems to be cell-dependent.

230 and expansion of HSCs in vitro has met with limited success because of incomplete knowledge regardin

231 ity for a specific target have been met with limited success because of the structural sensitivity of

232 rsion origin(s) and pathway(s) have met with limited success due to the patchiness of available data.

233 gs, its applicability to humans has met with limited success largely due to inefficient systemic deli

234 wever, these strategies have either met with limited success or cannot be readily extended to other l

235 ith new targets, these efforts have met with limited success since the early 1960s.

236 fferent strategies in the past have met with limited success until the development of statins.

237 devastating disease has so far been met with limited success, but emerging knowledge of neuroscience

238 nd non-pharmacologic therapies have met with limited success, in part due to an incomplete understand

239 These approaches have met with limited success, in part due to development of resistanc

240 ever, FLT3 inhibitors have thus far met with limited success, inducing only a clearance of peripheral

241 ck the emergence of resistance have met with limited success, largely because the mechanisms underlyi

242 r immunosuppression withdrawal have met with limited success, perhaps because they measure events dow

243 idiotype or tumor lysate, have been met with limited success, probably in part due to insufficient cr

244 enes for bipolar disorder (BD) have met with limited success, which has generally been attributed to

245 ajor depressive disorder (MDD) have met with limited success.

246 hies with pharmacologic agents have met with limited success.

247 susceptibility genes have thus far met with limited success.

248 ancer therapy has historically been met with limited success.

249 munogens bearing MPER epitopes have met with limited success.

250 es of DNA-histone interactions have met with limited success.

251 ADPglucose pyrophosphorylase, have met with limited success.

252 onversion efficiency have, however, met with limited success.

253 precise genetic contributions have met with limited success.

254 (HIV-1) vaccine antigens have been met with limited success.

255 vailable and current therapies have met with limited success.

256 such as common human diseases have met with limited success.

257 ls, specifically, in vivo in humans met with limited success.

258 iotic polymerization reactions have met with limited success.

259 by modifying it in various ways has met with limited success.

260 e system of the intact organism has met with limited success.

261 ogenitor cells (HPCs) in vitro have met with limited success.

262 same protocol to N-farnesyl lactams met with limited success.

263 e region of the solar spectrum have met with limited success.

264 ielded valuable information but has met with limited success.

265 ity genes for either phenotype have met with limited success.

266 and pathological heart murmurs have met with limited success.

267 ovirus-mediated gene transfer, have met with limited success.

268 n mammals, although these have been met with limited success.

269 ls expansion systems have, to date, met with limited success.

270 ion of suppressor T cell lines have met with limited success.

271 tments and surgical modalities have met with limited success.

272 s to better classify a disease have met with limited success.

273 c ductal adenocarcinoma (PDAC) have met with limited success.

274 nal approaches in bulk solution has met with limited success.

275 ng for N-nitrosamine formation have met with limited success.

276 C virus (HCV) in cell culture have met with limited success.

277 leukemia is an active area, but has met with limited success.

278 -targeted small molecule probes has met with limited success.

279 te self-sustaining populations have met with limited success.

280 apeutic options exist and have been met with limited success.

281 o define subtypes behaviorally have met with limited success.

282 ching the catalytic reactivity, has met with limited success.

283 ) of grey matter has been used for MTLE with limited success.

284 in relapsed/refractory multiple myeloma with limited success.

285 tropic and reducing agents, quite often with limited success.

286 oantigens have, in most cases, met only with limited success.

287 luated for enhanced cellular permeation with limited success.

288 n beta-thalassemia patient populations, with limited success in some cases, no universally effective

289 research focused on disease prevention, with limited success.

290 mall-molecule ligands has been rewarded with limited success.

291 SF6, once with air) over a week's span with limited success at re-attaching the DM.

292 for orthologous genes in other species with limited success.

293 e aimed to improve the kinetics of SrtA with limited success.

294 in both animals and humans are underway with limited success to date.

295 undance, DNA microarrays have been used with limited success to identify regulatory transcription fac

296 e methanol and liquid fuels in industry, yet limited success has been made to develop clean syngas pr

297 Currently available therapies yield limited success in treating such pain, suggesting the ne

298 amos National Laboratory (LANL) have yielded limited success in vaccine trials.

299 all-trans retinoic acid (ATRA) have yielded limited success, partially due to the epigenetic silenci

300 ing porous carbons to entrap PS have yielded limited success.